ACADIA Pharmaceuticals Inc
Ownership
Ownership Structure
Who owns ACADIA Pharmaceuticals Inc (ACAD)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 74.5% of the shares are freely tradable; institutional investors hold 99.1%.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Baker Bros Advisors LP | 24.90 | 42,896,690 | +0.0 | 03/31/2026 |
| BlackRock Inc | 12.51 | 21,550,921 | +3.8 | 03/31/2026 |
| Vanguard Portfolio Management, LLC | 5.03 | 8,671,645 | +0.0 | 03/31/2026 |
| State Street Corp | 4.84 | 8,332,771 | +5.3 | 03/31/2026 |
| RTW INVESTMENTS, LLC | 4.15 | 7,144,524 | +0.0 | 03/31/2026 |
| Vanguard Capital Management, LLC | 3.29 | 5,661,400 | +0.0 | 03/31/2026 |
| Dimensional Fund Advisors, Inc. | 2.14 | 3,694,988 | +17.1 | 06/30/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| iShares Core S&P Small-Cap ETF | 4.48 | 7,719,374 | -0.1 | 08/31/2026 |
| State Street® SPDR® S&P® Biotech ETF | 2.43 | 4,189,678 | -1.1 | 08/31/2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 2.38 | 4,095,404 | +0.5 | 07/31/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Insider holdings
| Person | Role | Shares | Value | As of | Type |
|---|---|---|---|---|---|
| Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | 67,828 | 1,865,270 $ | Aug 6, 2026 | direct |
| Thompson Elizabeth H.Z. | EVP, Head of Research & Dev | 18,994 | 522,335 $ | Jul 30, 2026 | direct |
Holdings as of each person's most recent SEC Form 4 filing — excluding options and RSUs, which are not shares yet. Holdings may have changed between two filings.
Insiders
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Aug 6, 2026 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Sell | 9,292 | 29.34 | 272,604 |
| Aug 6, 2026 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Sell | 5,000 | 29.00 | 145,000 |
| Aug 6, 2026 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Other | 14,292 | 17.84 | 254,969 |
| Aug 5, 2026 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Sell | 5,849 | 29.00 | 169,638 |
| Aug 5, 2026 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Other | 5,849 | 17.84 | 104,346 |
| Jul 30, 2026 | Thompson Elizabeth H.Z. | EVP, Head of Research & Dev | Sell | 50 | 26.17 | 1,309 |
| Jul 30, 2026 | Thompson Elizabeth H.Z. | EVP, Head of Research & Dev | Sell | 16,508 | 26.13 | 431,354 |
| Jul 29, 2026 | Thompson Elizabeth H.Z. | EVP, Head of Research & Dev | Other | 32,272 | – | – |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character. View all insider transactions →
Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.